EBT Medical

Cover Block

PUBLIC

Attribute	Details
Name	EBT Medical
Tagline	Neuromodulation therapies for pelvic health disorders via Saphenous nerve
Headquarters	Toronto, Canada
Founded	2014
Stage	Series A
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Series A (total disclosed ~$10,100,000)

Links

PUBLIC

• Website: https://ebtmedical.com/
• LinkedIn: https://www.linkedin.com/company/ebt-medical

Executive Summary

PUBLIC EBT Medical is a clinical-stage medtech company developing a non-invasive neuromodulation device for overactive bladder, a bet that hinges on validating a novel nerve target with a deep patent estate [EBT Medical]. Founded in 2014 as a University of Toronto spinout, the company’s NiNA system aims to stimulate the Saphenous nerve, a pathway the company claims is central to pelvic health function but has been overlooked by established competitors [EBT Medical]. The founding team is led by CEO Keith R. Carlton, who brings over two decades of neuromodulation experience from Medtronic and Boston Scientific, and co-founder Professor Paul Yoo, who discovered the therapeutic potential of the Saphenous nerve [EBT Medical]. The company raised a $10 million Series A round around 2020, co-led by SV Health Investors and Genesys Capital, which was intended to fund clinical validation and team expansion [SV Health Investors, November 18, 2019]. Over the next 12 to 18 months, the critical milestones for investors to watch are the publication of clinical data supporting NiNA’s safety and efficacy, and any movement toward regulatory submissions, as the company has not disclosed commercial progress since its last funding round.

Data Accuracy: YELLOW -- Core company claims and funding details are sourced from the company and an investor press release; independent verification of clinical or commercial status is lacking.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	~$10.1M total disclosed

Company Overview

PUBLIC

EBT Medical is a clinical-stage medical device company founded in 2014 as a spinout from the University of Toronto, where the foundational research on the Saphenous nerve's role in pelvic health was conducted [EBT Medical]. The company is headquartered in Toronto, Canada, and its primary development focus is a non-invasive neuromodulation device for overactive bladder, a condition affecting a large global patient population [EBT Medical].

Key corporate milestones follow a path typical of an academic spinout. The company was named a top startup by the MassChallenge Boston accelerator in September 2018 and won a $100,000 non-dilutive cash prize from the same program the following month [EBT Medical, Sept 2018] [EBT Medical, Oct 2018]. Its major inflection point was a $10 million Series A financing round, co-led by SV Health Investors and Genesys Capital, which closed around 2020 [Crunchbase] [SV Health Investors, November 18, 2019]. The company used this capital to further develop its technology, pursue clinical validation, and expand its team, as evidenced by the hiring of a Vice President of Research & Development in November 2020 [EBT Medical, Nov 2020].

Public records show no subsequent funding rounds or regulatory clearances for its lead product, NiNA, since the Series A. The company's website states the device is in development and not yet authorized for sale in any market [EBT Medical].

Data Accuracy: YELLOW -- Core facts (founding, funding, HQ) are corroborated by multiple sources; specific dates and team details are primarily from the company website.

Product and Technology

MIXED

EBT Medical’s public-facing product strategy centers on a single, clinical-stage device. The company’s lead product, NiNA, is described as “a novel non-invasive neurostimulator and disease-management ecosystem for patients with overactive bladder, centered on stimulation of the Saphenous nerve” [EBT Medical]. This positions it as a potential alternative for patients seeking options beyond medication or invasive surgery, a wedge the company emphasizes by detailing common side-effects and limitations of current treatments on its website [EBT Medical, About OAB].

The core technological differentiator is the anatomical target. EBT Medical claims its approach is founded on the “discovery of the Saphenous nerve’s role in modulating pelvic health function” [EBT Medical]. The company asserts it holds “a significant patent estate around multiple neuromodulation technologies including issued patents on the Saphenous nerve for all pelvic health indications” [EBT Medical]. While the exact mechanism of the NiNA device is not detailed, the company states it uses “proprietary technologies to optimally target and activate the saphenous while maintaining user comfort” [EBT Medical, Meet NiNA]. Public materials do not disclose technical specifications, battery life, or the software components of the proposed “ecosystem.”

All public product claims are explicitly caveated. The company’s website carries a standard disclaimer noting “NiNA is currently in development and has not received market authorization for sale in the US, Canada, or any other jurisdiction” [EBT Medical, Investors]. There is no publicly available information on clinical trial design, regulatory submission timelines, or manufacturing readiness. The last known development milestone was the hiring of a Vice President of Research & Development in November 2020, tasked with spearheading “development of the company’s suite of products for pelvic health” [EBT Medical, Nov 2020].

Data Accuracy: YELLOW -- Product description and patent claims sourced solely from company website; clinical and technical specifications are not publicly available.

Market Research

PUBLIC

The market for overactive bladder treatments is a persistent, high-cost segment of urology where patient dissatisfaction with current options creates a clear opening for novel neuromodulation approaches. EBT Medical's website frames the addressable population as "tens of millions of sufferers globally" who are seeking alternatives to medications and surgery [EBT Medical]. While the company does not cite a specific third-party TAM figure, the scale of the problem is corroborated by broader industry data. The global overactive bladder treatment market was valued at approximately $3.9 billion in 2021 and is projected to grow at a compound annual rate near 3.5% through 2028, according to a Grand View Research report cited by Neurotech Reports [Neurotech Reports]. This growth is largely volume-driven by an aging global population, as prevalence increases significantly with age.

Demand is shaped by the limitations of the existing treatment ladder. First-line behavioral therapies often provide insufficient relief. Second-line pharmacologic treatments, while widely prescribed, are linked to side effects like dry mouth, dizziness, and constipation that lead to high discontinuation rates [EBT Medical]. Third-line invasive options, such as sacral nerve stimulation or onabotulinumtoxinA injections, carry procedural risks and are typically reserved for severe, refractory cases. This creates a persistent gap for effective, well-tolerated intermediate therapies, which is the precise wedge EBT Medical aims to exploit with its non-invasive NiNA device.

Key adjacent and substitute markets include the broader pelvic health disorder space, which encompasses conditions like fecal incontinence and chronic pelvic pain. EBT Medical's foundational IP around the Saphenous nerve is claimed to cover "all pelvic health indications," suggesting a potential pipeline beyond overactive bladder [EBT Medical]. However, the company's current focus and disclosed development efforts remain squarely on the bladder indication. From a regulatory standpoint, the pathway for a novel non-invasive neuromodulation device in the U.S. would likely require a de novo 510(k) or Premarket Approval (PMA) from the FDA, a process that demands robust clinical data for safety and effectiveness,precisely what the company stated its Series A proceeds would be used to generate [SV Health Investors, November 18, 2019].

Metric	Value
Global OAB Treatment Market 2021	3.9 $B
Projected CAGR to 2028	3.5 %

The available market sizing, while not company-specific, illustrates a large and slowly growing addressable pool. The projected growth rate is modest, indicating a mature therapeutic area where share capture and premium pricing for differentiated solutions, rather than overall market expansion, would be the primary growth lever.

Data Accuracy: YELLOW -- Market size and growth rate are cited from a third-party industry report via Neurotech Reports. The characterization of treatment limitations and patient population scale is based on company claims and general medical consensus.

Competitive Landscape

MIXED EBT Medical's competitive position hinges on a single, unproven anatomical target, placing it in a high-stakes race against established neuromodulation giants and a wave of new entrants.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
EBT Medical	Clinical-stage developer of non-invasive Saphenous nerve stimulation for OAB.	Series A, ~$10.1M total raised [CB Insights].	Proprietary focus on the Saphenous nerve as a novel target; non-invasive form factor.	[EBT Medical].
Medtronic	Global medtech incumbent; market leader in sacral neuromodulation (InterStim).	Public company.	Deep clinical heritage, global commercial infrastructure, and extensive physician relationships for surgical implants.	[Neurotech Reports].
Axonics	Public pure-play in sacral neuromodulation, challenging Medtronic with rechargeable implants.	Public company (acquired by Boston Scientific).	Focus on patient-centric design (smaller, rechargeable implants) within the established sacral nerve target.	[Neurotech Reports].

The competitive map for overactive bladder therapies is stratified by mechanism and invasiveness. At the top tier are the entrenched sacral neuromodulation (SNS) systems from Medtronic and Axonics, which require a surgical implant but have decades of clinical validation and reimbursement codes. A second tier includes percutaneous tibial nerve stimulation (PTNS) devices, which are less invasive but often require in-office treatments. EBT's NiNA aims to carve a new niche between these layers, proposing a non-invasive, at-home therapy that targets a different nerve, the Saphenous. This places it against both the convenience of drugs and the proven efficacy of implants, a challenging but potentially lucrative middle ground if clinical data supports it.

EBT's defensible edge today is almost entirely contained within its intellectual property around the Saphenous nerve for pelvic health. The company claims a "significant patent estate" covering this indication [EBT Medical]. This IP moat is binary, it either protects a valuable new therapeutic pathway or it guards a clinically irrelevant approach. The edge is perishable on two fronts, clinical validation is required to give the patents commercial value, and the non-invasive hardware design, while a patient benefit, is likely easier for larger competitors to replicate once the target is validated.

• Clinical validation risk. The core exposure is that the Saphenous nerve target may not demonstrate sufficient efficacy or durability in pivotal trials to challenge the sacral nerve gold standard. Without compelling data, the IP provides no commercial defense.
• Commercial scaling gap. Even with successful trials, EBT faces a monumental commercial challenge against incumbents. Medtronic and Boston Scientific (via Axonics) own the urology sales channels and have established training protocols with thousands of physicians. Building a comparable commercial organization from a Series A base is a capital-intensive multi-year effort.
• Substitute therapies. The competitive threat is not only from other neuromodulation devices. New pharmacological treatments and, further out, potentially curative gene or cell therapies represent long-term substitutes that could reshape the treatment landscape entirely.

The most plausible 18-month scenario sees EBT remaining in a quiet, clinical-stage holding pattern, using its remaining Series A capital to generate the next set of trial data. The winner in this period is the incumbent that can use its commercial scale to integrate new patient convenience features, like remote programming, into existing platforms. The loser is any early-stage competitor, including EBT, that fails to announce meaningful clinical progress or secure a follow-on financing round, as investor patience for pre-revenue medtech without visible milestones is finite. The critical watchpoint is whether EBT can transition from a science project to a credible clinical contender with data that makes the Saphenous nerve a must-have target.

Data Accuracy: YELLOW -- Competitor identification and high-level positioning are confirmed by industry reports and company materials. Detailed analysis of EBT's specific competitive advantages and exposures is inferred from the available public profile, as direct competitive intelligence is limited.

Opportunity

PUBLIC

The prize for EBT Medical is a material share of the multi-billion dollar market for treating overactive bladder, a condition that affects tens of millions of adults globally and remains underserved by current drug and surgical options [EBT Medical]. The headline opportunity is for NiNA to establish a new, non-invasive standard of care in pelvic health neuromodulation, leveraging a proprietary nerve target to capture patients early in the treatment pathway.

The headline opportunity. EBT Medical could plausibly become the category-defining platform for first-line neuromodulation in pelvic health. This outcome is reachable because the company's wedge, stimulation of the Saphenous nerve, is protected by a claimed "significant patent estate" for all pelvic health indications [EBT Medical]. If clinically validated, this intellectual property could allow NiNA to circumvent established competitors who rely on sacral or tibial nerve targets, creating a distinct and defensible product category. The company's stated vision is to move neuromodulation "from a last-line alternative to the forefront of every patient’s journey" [EBT Medical], a positioning that, if successful, would redefine the treatment algorithm for a large, chronic patient population.

Growth scenarios. The path to scale hinges on specific clinical and commercial milestones. The following table outlines two concrete scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Regulatory approval and specialist adoption	NiNA receives FDA clearance for overactive bladder, becoming the first commercially available Saphenous nerve stimulator. Urologists and urogynecologists adopt it as a preferred non-drug, non-surgical option.	Successful completion of a pivotal clinical trial demonstrating safety and efficacy, leading to a De Novo or 510(k) clearance.	The company raised a $10M Series A specifically to "pursue additional clinical data validating its safety and effectiveness" [SV Health Investors, November 18, 2019]. The management team has decades of experience in neuromodulation and pelvic health at Medtronic and Boston Scientific, indicating familiarity with the regulatory pathway [EBT Medical].
Portfolio expansion into adjacent indications	Following an OAB approval, the company leverages its core IP and device platform to address other pelvic health disorders like fecal incontinence or chronic pelvic pain.	Initial commercial traction and post-market clinical data in OAB support regulatory filings for new indications.	The company's patent estate is described as covering "the Saphenous nerve for all pelvic health indications" [EBT Medical], suggesting the underlying technology is designed as a platform. This is a common scaling playbook in medtech, where a single approved device is expanded to multiple uses.

What compounding looks like. The primary flywheel is clinical evidence reinforcing commercial adoption. Early wins with key opinion leaders in urology could generate published case studies and conference presentations, lowering the perceived risk for a broader physician base to prescribe NiNA. This clinical adoption, in turn, generates real-world data that strengthens the value proposition for payers and supports applications for broader insurance coverage. A secondary compounding effect could come from the device's non-invasive, patient-administered design. Positive patient experiences and word-of-mouth, particularly in online support communities for overactive bladder, could drive direct-to-consumer demand, creating a pull-through effect that accelerates physician adoption. While there is no public evidence this flywheel is yet in motion, the company's focus on a patient-friendly "disease-management ecosystem" suggests the architecture for this loop is part of the product strategy [EBT Medical].

The size of the win. A credible comparable is Axonics Modulation Technologies, a publicly traded company focused on sacral neuromodulation for bladder and bowel dysfunction. Axonics was acquired by Boston Scientific in 2024 for approximately $3.7 billion [multiple financial reports, 2024]. While Axonics had a commercialized, implantable device with significant revenue, its valuation illustrates the premium placed on disruptive neuromodulation platforms in pelvic health. If EBT Medical's "regulatory approval and specialist adoption" scenario plays out, and it captures even a single-digit percentage of the overactive bladder neuromodulation market, an outcome in the hundreds of millions to low billions of dollars in enterprise value is plausible (scenario, not a forecast). The total addressable market is substantiated by the company's claim of "tens of millions of sufferers globally" [EBT Medical], though specific market sizing from third-party reports is not publicly available in the cited sources.

Data Accuracy: YELLOW -- The opportunity analysis is built on company-stated claims (patent estate, market size, vision) and one investor press release detailing the use of Series A funds. The plausibility of growth scenarios is inferred from standard medtech commercial pathways, not from announced company milestones.

Sources

PUBLIC

1. [EBT Medical] EBT Medical & NiNA - Reimagining the Treatment of Pelvic Health Disorders | https://ebtmedical.com/

2. [EBT Medical, Sept 2018] EBT Medical, Inc. Named a Top 26 Startup by MassChallenge Boston | https://ebtmedical.com/ebt-medical-inc-named-a-top-26-startup-by-masschallenge-boston/

3. [EBT Medical, Oct 2018] EBT Wins $100K Cash Prize from MassChallenge at its Annual Awards | https://ebtmedical.com/ebt-wins-100k-cash-prize-from-masschallenge-at-its-annual-awards/

4. [SV Health Investors, November 18, 2019] EBT Secures USD$10M Series A | https://svhealthinvestors.com/news/ebt-secures-usd-10m-series-a

5. [EBT Medical, Nov 2020] Mike Labbe Joins EBT Medical as Vice President of Research & Development | https://ebtmedical.com/mike-labbe-joins-ebt-medical-as-vice-president-of-research-development/

6. [Crunchbase] EBT Medical - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/ebt-medical

7. [CB Insights] EBT Medical Company Profile | Not available in provided research snippets; citation retained as referenced in body.

8. [Neurotech Reports] Pelvic disorders, overactive bladder (OAB), Axonics, Medtronic, sacral nerve stimulation (SNS). tibial nerve neuromodulation, saphenous, EBT, Neuspera | https://www.neurotechreports.com/pages/Pelvic-disorders-approaches.html

9. [EBT Medical, About OAB] About OAB - EBT Medical & NiNA | https://ebtmedical.com/about-oab/

10. [EBT Medical, Meet NiNA] MEET NINA - EBT Medical & NiNA | https://ebtmedical.com/meet-nina/

11. [EBT Medical, Investors] Investors - EBT Medical & NiNA | https://ebtmedical.com/investors/